Bioelectronics Corp (BIEL)

[4toSchool]

Posting financials with positive trends will indeed help the BIEL PPS.


Here are a few risks to investors that currently suppress the PPS.
- The Related Party Notes with the holder's option to convert the debt that they hold to 41,735,939,447 billion shares
- The AS is pretty much maxed out and may need to be raised to provide additional working capital.
- As of 12-31-2020, Current Assets were $425,167, while the Current Liabilities were $8,843,178.
- KT-Tape has an exclusive in their space. How much price pressure can KT-Tape exert on BIEL's OEM pricing?
- KT-Tape has an exclusive in this space. This limits our ability to expand sales.
- BIEL lost money in the 4th quarter, 2020, and for the entire year.
- KW and PW collected no interest in 2020. Will they in the future? Nearly $1 million in annual expenses could reappear at any time.
- Payment of the SEC fine is long overdue. There could be negative ramifications of this delinquency.
- Will other products, like Allay, gain FDA clearance?
- An inexperienced CEO, President, CFO, Treasurer, Executive Board Member.

Some of these investor risks that IMO are harming the PPS, could be mitigated with positive information and action from BIEL management.

I guess that the BIEL train has run out of fuel. Hopefully, our exclusive relationship with KT-Tape will provide the needed fuel. I am hopeful that KT-Tape can sell this product. If they can't IMO, no one can, but it is too early to tell.